2026-08-20T07:36:26-05:00 2025-12-31 141442607 BST & CO CPAS LLP 10 BRITISH AMERICAN BLVD LATHAM NY 12110 990 2025-01-01 203654626 REGENERATIVE RESEARCH FOUNDATION REGE 5186948188 150 NEW SCOTLAND AVENUE ALBANY NY 12208 WILLIAM KAHN CPA CHAIR 5186948188 2026-07-28 1 NICHOLAS MURABITO P02354743 5184596700 2026-07-28 2025 2025-03-06 01:10:19Z NEURAL STEM CELL INSTITUTE WILLIAM KAHN CPA 150 NEW SCOTLAND AVENUE ALBANY NY 12208 7965326 0 X WWW.NEURALSCI.ORG X 2005 NY THE PRINCIPAL MISSION OF THE REGENERATIVE RESEARCH FOUNDATION IS TO DEVELOP REGENERATIVE STEM CELL THERAPIES FOR DISEASES OF THE CENTRAL NERVOUS SYSTEM (CNS): THE BRAIN, SPINAL CORD, AND RETINA. 7 6 43 16 0 0 5982290 7396591 782345 250843 75008 133890 166895 184002 7006538 7965326 0 0 0 0 3003454 2978732 0 0 9333 3487594 4098031 6491048 7076763 515490 888563 9028494 10216177 3000354 3299474 6028140 6916703 X THE PRINCIPAL MISSION OF THE REGENERATIVE RESEARCH FOUNDATION IS TO DEVELOP REGENERATIVE STEM CELL THERAPIES FOR DISEASES OF THE CENTRAL NERVOUS SYSTEM (CNS): THE BRAIN, SPINAL CORD, AND RETINA. 0 0 1012342 DESPITE MANY CHALLENGES IN FISCAL YEAR 2025 THE REGENERATIVE RESEARCH FOUNDATION CONTINUED TO PURSUE ITS RESEARCH MISSION. DURING THE YEAR FOUNDATION RESEARCHERS PUBLISHED THIRTEEN ARTICLES IN PROMINENT SCIENTIFIC JOURNALS REPORTING THE RESULTS OF THEIR INVESTIGATIONS INTO NEURODEGENERATIVE DISEASES SUCH AS DEMENTIA, MACULAR DEGENERATION AND POTENTIAL TREATMENTS FOR NEURODEGENERATIVE DISEASES. THESE PUBLICATIONS ARE AVAILABLE TO THE RESEARCH COMMUNITY AND GENERAL PUBLIC FREE OF CHARGE THROUGH THE NATIONAL LIBRARY OF MEDICINE OPEN ACCESS REPOSITORY. THE FOUNDATION RESEARCHERS CONTINUE TO PREPARE FUNDING APPLICATIONS WHICH WILL SUPPORT THEIR RESEARCH ACTIVITIES. THE FOUNDATION CONTINUED TO DEVELOP AND IMPROVE ITS PRODUCTION OF HUMAN STEM CELL ORGANOID MODELS AS AN ALTERNATIVE TO THE USE OF ANIMAL MODELS. THESE EFFORTS ARE ENDORSED BY THE NIH AND FDA COMPLEMENT-ARIE INITIATIVES THAT PROMOTE NEW APPROACH METHODOLOGY (NAM) TO REDUCE ANIMAL USE IN DRUG DEVELOPMENT. THE FOUNDATION'S CORE FACILITY, NEURACELL, CONTINUES TO PROVIDE BRAIN REGION-SPECIFIC ORGANOIDS TO RESEARCHERS AROUND THE COUNTRY. 1013548 250843 THE CONTINUING PHASE 1/2A CLINICAL TRIAL TREATED ITS 12TH SUBJECT COMPLETING THE SECOND COHORT OF AN 18-SUBJECT TRIAL. THE FOUNDATION'S SCIENTIFIC DIRECTOR, DR. SALLY TEMPLE-STERN, DELIVERED THE CLOSING KEYNOTE ADDRESS AT THE 2026 ASSOCIATION FOR RESEARCH IN VISION AND OPHTHALMOLOGY MEETING (THE MAJOR MEETING FOR OPHTHALMIC RESEARCH). THE SAFETY AND EFFICACY RESULTS OF THE LOW DOSE PHASE OF THE TRIAL WERE PUBLISHED DURING THE YEAR 2025. 4103203 THE ALZHEIMER'S DISEASE AND RELATED DEMENTIAS RESEARCH PROGRAM CONTINUES ITS MISSION TO EXPAND THE UNDERSTANDING AND DEVELOPMENT OF A POTENTIAL TREATMENT FOR THESE NEURODEGENERATIVE DISEASES. THE INSTITUTE CONTINUES TO SERVE AS THE LEAD ORGANIZATION FOR A CONSORTIUM OF INSTITUTIONS AND INVESTIGATORS FUNDED BY THE NATIONAL INSTITUTES OF HEALTH AND OTHER PRIVATE FOUNDATIONS WHICH IS FOCUSED ON IDENTIFYING GENES ASSOCIATED WITH THE DEVELOPMENT OF DEMENTIA. THE FOUNDATION CONTINUES ITS SEARCH FOR A BIOTECH PARTNER TO SUPPORT RESEARCH AND DEVELOPMENT OF A PROMISING NEURODEGENERATIVE DISEASE TREATMENT UNDER DEVELOPMENT BY THE FOUNDATION. 6129093 1 1 0 0 0 0 0 0 0 0 1 0 0 1 1 1 1 0 0 0 0 0 0 0 0 0 0 0 0 1 0 0 0 0 0 1 1 0 0 0 0 0 0 0 0 0 0 1 1 0 1 43 1 0 0 0 0 0 0 0 0 0 0 0 0 X 7 6 1 0 0 0 0 0 0 1 1 0 0 1 1 1 1 1 1 1 1 1 1 NY X X THOMAS J IRWIN 5186948189 150 NEW SCOTLAND AVE ALBANY NY 12208 WILLIAM KAHN CPA CHAIR 5.00 X X 0 0 0 JEFFREY H STERN MD PHD DIRECTOR FOR TRANSLATIONAL RESEARCH 30.00 X X 53025 0 0 VITO GRASSO MPA CAE DIRECTOR 1.00 X 0 0 0 DAVID O CARPENTER MD DIRECTOR 1.00 X 0 0 0 DAWN ABBUHL DIRECTOR 1.00 X 0 0 0 ROBERT CATALANO MD DIRECTOR 1.00 X 0 0 0 AMY G KLANN PHD JD DIRECTOR 1.00 X 0 0 0 SALLY TEMPLE-STERN PHD EXECUTIVE & SCIENTIFIC DIRECTOR 65.00 X 170986 0 23994 CAITLIN HILL PRINCIPAL INVESTIGATOR 40.00 X 136509 0 5174 THOMAS KIEHL PRINCIPAL INVESTIGATOR 40.00 X 131142 0 14051 GLENNA FORD PROJECT MANAGER 40.00 X 139103 0 14462 DAVID BUTLER PHD PRINCIPAL INVESTIGATOR 40.00 X 101617 0 4037 TAYLOR BERTUCCI PHD PRINCIPAL INVESTIGATOR 40.00 X 102614 0 3505 834996 0 65223 6 0 1 0 0 6596455 800136 7396591 SPONSORED RESEARCH 541700 250843 250843 250843 133890 133890 13133 13133 NEURACELL INCOME 541700 144098 144098 OTHER 541700 26771 26771 170869 7965326 250843 0 317892 248005 238256 9749 2249323 1675821 565946 7556 81140 65175 15676 289 207442 166843 39865 734 192822 157189 35002 631 153332 153332 23820 23820 360789 328956 31833 36477 21550 14927 37906 1761 36041 104 370668 346681 23987 25714 20003 5711 15737 7730 8007 25 25 203526 203526 32954 32954 RESEARCH SUBCONTRACTS 1893279 1893279 LABORATORY CHARGES 816052 769559 46474 19 EQUIP. REPAIR & MAINT. 67619 58391 9228 OTHER EXPENSES 60133 21041 39092 7076763 6129093 938337 9333 37872 3500 4962960 6606023 921305 922104 34828 42616 110640 88911 4651426 4017383 734099 634043 2226790 1918980 9028494 10216177 774115 1060071 2226239 2239403 3000354 3299474 X 4780002 5709885 1248138 1206818 6028140 6916703 9028494 10216177 888563 0 X 0 1 X 1 1 1 X 4650213 6469338 7786968 5982290 7396591 32285400 4650213 6469338 7786968 5982290 7396591 32285400 1154862 31130538 7275 27808 83729 91182 147023 357017 160911 457432 224548 150722 170869 1164482 33806899 2591809 0.92080 0.89670 X SCHEDULE A, PART II, LINE 10, EXPLANATION OF OTHER INCOME: MISCELLANEOUS - 2023 AMOUNT: $ 18,816. 2024 AMOUNT: $ 4,953. 2025 AMOUNT: $ 26,771. NEURACELL INCOME - 2021 AMOUNT: $ 160,911. 2022 AMOUNT: $ 457,432. 2023 AMOUNT: $ 205,732. 2024 AMOUNT: $ 145,769. 2025 AMOUNT: $ 144,098. RESTRICTED RESTRICTED RESTRICTED RESTRICTED RESTRICTED RESTRICTED RESTRICTED RESTRICTED 75353 33695 41658 4576073 3983688 592385 634043 OTHER RECEIVABLE 12660 ROU ASSET - OPERATING LEASE (GAAP PRESENTATION PURPOSES ONLY) 1906320 1918980 OPERATING LEASE LIABILITY (GAAP PRESENTATION PURPOSES ONLY) 2239403 2239403 X 7965326 0 7965326 0 7965326 7076763 0 7076763 0 7076763 PART X, LINE 2: THE FOUNDATION FILES FORM 990 ANNUALLY WITH THE INTERNAL REVENUE SERVICE. WHEN ANNUAL RETURNS ARE FILED, SOME TAX POSITIONS TAKEN ARE HIGHLY CERTAIN TO BE SUSTAINED UPON EXAMINATION BY THE TAXING AUTHORITIES, WHILE OTHER TAX POSITIONS ARE SUBJECT TO UNCERTAINTY ABOUT THE TECHNICAL MERITS OF THE POSITION OR AMOUNT OF THE POSITION'S TAX BENEFIT THAT WOULD ULTIMATELY BE SUSTAINED. MANAGEMENT EVALUATED THE FOUNDATION'S TAX POSITIONS, INCLUDING INTEREST AND PENALTIES ATTRIBUTABLE THERETO, AND CONCLUDED THAT THE FOUNDATION HAD TAKEN NO TAX POSITION THAT REQUIRED ADJUSTMENT IN ITS FINANCIAL STATEMENTS AS OF DECEMBER 31, 2025 OR 2024. X X 0 0 0 0 0 0 0 0 0 SALLY TEMPLE-STERN PHD EXECUTIVE & SCIENTIFIC DIRECTOR 170986 0 0 0 0 0 7200 0 16794 0 194980 0 0 0 GLENNA FORD PROJECT MANAGER 138504 0 599 0 0 0 5600 0 8862 0 153565 0 0 0 SALLY TEMPLE-STERN SEE PART V 194980 SEE PART V 0 JEFFREY H STERN SEE PART V 53025 SEE PART V 0 SCHEDULE L, PART IV, LINE 1, COLUMN B: SALLY TEMPLE-STERN IS THE EXECUTIVE AND SCIENTIFIC DIRECTOR OF THE ORGANIZATION AND ALSO HAS A FAMILY RELATIONSHIP WITH A CURRENT BOARD MEMBER. SCHEDULE L, PART IV, LINE 1, COLUMN D: SALLY TEMPLE-STERN IS COMPENSATED FOR SERVICES PERFORMED AS THE EXECUTIVE AND SCIENTIFIC DIRECTOR OF THE ORGANIZATION. HER COMPENSATION IS DETERMINED BY THE GOVERNING BOARD AS DISCLOSED IN SCHEDULE O. SCHEDULE L, PART IV, LINE 2, COLUMN B: JEFFREY H. STERN IS THE TRANSLATIONAL RESEARCH DIRECTOR OF THE ORGANIZATION AND ALSO HAS A FAMILY RELATIONSHIP WITH A CURRENT OFFICER. SCHEDULE L, PART IV, LINE 2, COLUMN D: JEFFREY H. STERN IS COMPENSATED FOR SERVICES PERFORMED AS THE TRANSLATIONAL RESEARCH DIRECTOR OF THE ORGANIZATION. HIS COMPENSATION IS DETERMINED BY THE GOVERNING BOARD AS DISCLOSED IN SCHEDULE O. FORM 990, PART VI, SECTION A, LINE 2 DR. JEFFREY STERN AND DR. SALLY TEMPLE-STERN HAVE A FAMILY AND BUSINESS RELATIONSHIP. FORM 990, PART VI, SECTION B, LINE 11B A COPY OF THE ORGANIZATION'S FORM 990 WAS DISTRIBUTED TO AND REVIEWED BY THE BOARD PRIOR TO FILING WITH THE IRS. FORM 990, PART VI, SECTION B, LINE 12C EVERY BOARD MEMBER IS PROVIDED A COPY OF THE CONFLICT OF INTEREST POLICY AND ALL RELATIONSHIPS INVOLVING AN APPARENT OR POTENTIAL CONFLICT OF INTEREST ARE DISCUSSED BY THE BOARD IN ADVANCE OF THE FOUNDATION ENTERING INTO ANY TRANSACTION OR RELATIONSHIP. THE BOARD ALSO REVIEWS ITS CONFLICT OF INTEREST POLICY ANNUALLY. FORM 990, PART VI, SECTION B, LINE 15 THE COMPENSATION OF ALL EMPLOYEES INCLUDING THE FOUNDATION'S EXECUTIVE DIRECTOR AND OTHER INDIVIDUALS IS REVIEWED AND APPROVED PERIODICALLY BY THE GOVERNING BOARD. THE BOARD CONSIDERS BOTH COMPARATIVE POSITIONS AND GEOGRAPHIC FACTORS WHEN MAKING ITS DECISION. FORM 990, PART VI, SECTION C, LINE 19 ALL FOUNDATION GOVERNING DOCUMENTS, CONFLICT OF INTEREST POLICY, AND FINANCIAL STATEMENTS ARE AVAILABLE TO THE PUBLIC UPON REQUEST EITHER IN PERSON, BY TELEPHONE OR EMAIL.